title: Controversies in heparin monitoring.
authors.affiliation: Departments of Pathology and Medicine, Hematology, Stanford University School of Medicine, California 94305, USA. zehnder@stanford.edu
authors.forename: James
authors.initials: J
authors.lastname: Zehnder
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Price
authors.forename: Jing
authors.initials: J
authors.lastname: Jin
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D016903:Drug Monitoring; D004935:Esophageal Diseases / Q000097:blood / Q000150:complications / Q000628:therapy; D005268:Femoral Vein; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D006975:Hypertension, Portal / Q000097:blood / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014648:Varicose Veins / Q000097:blood / Q000150:complications / Q000628:therapy; D020246:Venous Thrombosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D005343:Fibrinolytic Agents; D006493:Heparin